The uncomfortable question lingers. In those nine years, how many died prematurely or endured avoidable disease progression because subsidised access was not available? If ministerial intervention was critical to this outcome, why did the system require it again? …
The nine-year wait should raise some important but uncomfortable questions - can we be better?
March 1, 2026 Latest NewsBioPharmaComment
Latest Video
Georgia Forrest
New Stories
-
Setting the standard for safe and accountable virtual healthcare in Australia
March 4, 2026 - - Latest News -
A system built for a past is struggling to meet the challenge of today, let alone the future
March 4, 2026 - - Latest News -
Firebrick Pharma targets breakout year in 2026 as Nasodine expansion accelerates
March 4, 2026 - - Australian Biotech -
AdAlta strengthens clinical push for breakthrough solid cancer therapy
March 4, 2026 - - Australian Biotech -
Island Pharmaceuticals deepens US biodefence ties to advance Marburg treatment
March 4, 2026 - -
PYC Therapeutics secures strong backing as retail offer adds $47 million to capital raise
March 4, 2026 - - Australian Biotech -
Alterity strengthens clinical leadership with appointment of neurologist Daniel Claassen
March 4, 2026 - - Australian Biotech